PHAXIAM Therapeutics Management
Management criteria checks 2/4
PHAXIAM Therapeutics' CEO is Thibaut Fayet, appointed in Jun 2023, has a tenure of 1.58 years. total yearly compensation is €391.73K, comprised of 34.5% salary and 65.5% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth €9.36K. The average tenure of the management team and the board of directors is 1.6 years and 11.7 years respectively.
Key information
Thibaut Fayet
Chief executive officer
€391.7k
Total compensation
| CEO salary percentage | 34.5% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 1.6yrs |
| Board average tenure | 11.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€23m |
| Dec 31 2023 | €392k | €135k | -€23m |
Compensation vs Market: Thibaut's total compensation ($USD407.24K) is about average for companies of similar size in the German market ($USD462.70K).
Compensation vs Earnings: Insufficient data to compare Thibaut's compensation with company performance.
CEO
Thibaut Fayet (56 yo)
1.6yrs
Tenure
€391,725
Compensation
Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.6yrs | €391.73k | 0.055% € 9.4k | |
| Deputy CEO | 5yrs | €262.41k | 0.0038% € 645.7 | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 2yrs | no data | no data | |
| Director Investor Relations | no data | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | no data | |
| Consultant & Member of Scientific Board | no data | no data | no data | |
| Consultant & Member of Scientific Board | no data | no data | no data | |
| Consultant & Member of Scientific Board | no data | no data | no data | |
| Consultant & Member of Scientific Board | no data | no data | no data | |
| Consultant & Member of Scientific Board | no data | no data | no data |
1.6yrs
Average Tenure
56yo
Average Age
Experienced Management: 2E40's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Consultant & Member of Scientific Board | 15yrs | no data | no data | |
| Consultant & Member of Scientific Board | 15.3yrs | no data | no data | |
| Consultant & Member of Scientific Board | 13yrs | no data | no data | |
| Consultant & Member of Scientific Board | 13yrs | no data | no data | |
| Consultant & Member of Scientific Board | 13yrs | no data | no data | |
| Independent Director | 11.7yrs | €68.00k | 0.010% € 1.8k | |
| Vice Chairman | 11.7yrs | €1.00m | 0.0048% € 825.1 | |
| Independent Director | 10.3yrs | €56.75k | no data | |
| Chairman of the Board | 1.6yrs | €153.18k | no data | |
| Representative Director | 1.6yrs | €26.25k | no data | |
| Independent Director | 1.6yrs | €21.75k | no data | |
| Independent Director | less than a year | no data | no data |
11.7yrs
Average Tenure
65yo
Average Age
Experienced Board: 2E40's board of directors are seasoned and experienced ( 11.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 09:21 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PHAXIAM Therapeutics S.A. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mathieu Chabert | Bryan Garnier & Co |
| Guillaume Cuvillier | Gilbert Dupont |
| Philippa Gardner | Jefferies LLC |